Skip to main content
Journal cover image

Menopausal hormone therapy use and long-term all-cause and cause-specific mortality in the Long Island Breast Cancer Study Project.

Publication ,  Journal Article
Wang, T; Bradshaw, PT; Moorman, PG; Nyante, SJ; Nichols, HB; Shantakumar, S; Parada, H; Khankari, NK; Terry, MB; Teitelbaum, SL; Neugut, AI ...
Published in: Int J Cancer
December 15, 2020

Previous studies have observed a reduced mortality risk associated with menopausal hormone therapy (MHT) use among breast cancer survivors. We sought to clarify whether such association could be explained by tumor heterogeneity, specific causes of death, confounding from comorbidities or health behaviors, and a comparison group of women without breast cancer. We interviewed 1508 women newly diagnosed with first primary breast cancer in 1996 to 1997 (~3 months after diagnosis), and 1556 age-matched women without breast cancer, about MHT use history. The National Death Index was used to ascertain vital status after a median of 17.6 years of follow-up (N = 597 deaths for breast cancer subjects). Multivariable-adjusted Cox proportional hazards regression was used to estimate hazard ratios (HRs) and 95% confidence intervals (95%CIs) for all-cause mortality, and cause-specific HR (cHR) for breast cancer and cardiovascular disease (CVD). The Fine-Gray model was used to account for competing causes of death. Among women with breast cancer, ever vs never MHT use was inversely associated with all-cause (HR = 0.77, 95%CI = 0.62-0.95), breast cancer-specific (cHR = 0.69, 95%CI = 0.48-0.98), and CVD-specific mortality (cHR = 0.57, 95%CI = 0.38-0.85). Difference of the association was observed in breast cancer-specific mortality according to hormone receptor status (negative tumors: cHR = 0.44, 95%CI = 0.19-1.01; positive tumors: cHR = 0.96, 95%CI = 0.60-1.53). Among the comparison group, we observed similar, but more modest inverse associations for all-cause and CVD-specific mortality. MHT use was inversely associated with mortality after breast cancer, even after accounting for competing causes of death and multiple confounders, and was evident among women without breast cancer. Potential heterogeneity by hormone receptor status requires more study.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Int J Cancer

DOI

EISSN

1097-0215

Publication Date

December 15, 2020

Volume

147

Issue

12

Start / End Page

3404 / 3415

Location

United States

Related Subject Headings

  • Proportional Hazards Models
  • Oncology & Carcinogenesis
  • New York
  • Middle Aged
  • Menopause
  • Humans
  • Hormone Replacement Therapy
  • Female
  • Cause of Death
  • Case-Control Studies
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Wang, T., Bradshaw, P. T., Moorman, P. G., Nyante, S. J., Nichols, H. B., Shantakumar, S., … Gammon, M. D. (2020). Menopausal hormone therapy use and long-term all-cause and cause-specific mortality in the Long Island Breast Cancer Study Project. Int J Cancer, 147(12), 3404–3415. https://doi.org/10.1002/ijc.33174
Wang, Tengteng, Patrick T. Bradshaw, Patricia G. Moorman, Sarah J. Nyante, Hazel B. Nichols, Sumitra Shantakumar, Humberto Parada, et al. “Menopausal hormone therapy use and long-term all-cause and cause-specific mortality in the Long Island Breast Cancer Study Project.Int J Cancer 147, no. 12 (December 15, 2020): 3404–15. https://doi.org/10.1002/ijc.33174.
Wang T, Bradshaw PT, Moorman PG, Nyante SJ, Nichols HB, Shantakumar S, et al. Menopausal hormone therapy use and long-term all-cause and cause-specific mortality in the Long Island Breast Cancer Study Project. Int J Cancer. 2020 Dec 15;147(12):3404–15.
Wang, Tengteng, et al. “Menopausal hormone therapy use and long-term all-cause and cause-specific mortality in the Long Island Breast Cancer Study Project.Int J Cancer, vol. 147, no. 12, Dec. 2020, pp. 3404–15. Pubmed, doi:10.1002/ijc.33174.
Wang T, Bradshaw PT, Moorman PG, Nyante SJ, Nichols HB, Shantakumar S, Parada H, Khankari NK, Terry MB, Teitelbaum SL, Neugut AI, Gammon MD. Menopausal hormone therapy use and long-term all-cause and cause-specific mortality in the Long Island Breast Cancer Study Project. Int J Cancer. 2020 Dec 15;147(12):3404–3415.
Journal cover image

Published In

Int J Cancer

DOI

EISSN

1097-0215

Publication Date

December 15, 2020

Volume

147

Issue

12

Start / End Page

3404 / 3415

Location

United States

Related Subject Headings

  • Proportional Hazards Models
  • Oncology & Carcinogenesis
  • New York
  • Middle Aged
  • Menopause
  • Humans
  • Hormone Replacement Therapy
  • Female
  • Cause of Death
  • Case-Control Studies